Soo-A Jung
Overview
Explore the profile of Soo-A Jung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park Y, Kim J, Ryu Y, Moon J, Shin Y, Kim J, et al.
Cancer Biol Ther
. 2023 Aug;
24(1):2246208.
PMID: 37621144
Significant improvement in targeted therapy for colorectal cancer (CRC) has occurred over the past few decades since the approval of the EGFR inhibitor cetuximab. However, cetuximab is used only for...
2.
Kim D, Ryu Y, Lee E, Koh D, Moon J, Jung S, et al.
Invest New Drugs
. 2022 Dec;
41(1):105-114.
PMID: 36538258
Dysregulated Wnt signaling is associated with malignant oncogenic transformation, especially in colon cancer. Recently, numerous drugs have been developed based on tumorigenesis biomarkers, thus having high potential as drug targets....
3.
Hong J, Kim D, Shin J, Ryu Y, Moon J, Koh D, et al.
Anticancer Res
. 2022 Mar;
42(4):1813-1819.
PMID: 35346999
Background/aim: Colorectal cancer is reported to have the highest mortality rate among human malignancies. Although many research results for the treatment of colorectal cancer have been reported, there is no...
4.
Hong S, Shin J, Moon J, Jung S, Koh D, Ryu Y, et al.
Invest New Drugs
. 2020 May;
38(6):1696-1706.
PMID: 32462369
Inhibitor of apoptosis proteins (IAPs) are overexpressed in the majority of cancers and prevent apoptosis by inhibiting caspases. IAPs have therefore attracted considerable attention as potential targets for anticancer therapy....
5.
Kim D, Kim M, Moon J, Lee E, Hong J, Lee S, et al.
Biochem Biophys Res Commun
. 2020 May;
527(1):305-310.
PMID: 32446385
Non-small lung cancer (NSCLC) is the most common cancer in the world. The epidermal growth factor receptor (EGFR) gene is mutated in approximately 10% of lung cancer cases in the...
6.
Kim T, Han H, Lee K, Zang D, Rha S, Park Y, et al.
Gastric Cancer
. 2019 Apr;
22(6):1206-1214.
PMID: 30945121
Background: Poziotinib (HM781-36B) is an irreversible pan-HER tyrosine kinase inhibitor which targets EGFR, HER2, and HER4. This prospective, multicenter, open-label, phase I/II study determined the maximum tolerated dose (MTD) and...
7.
Moon J, Hong S, Kim J, Shin J, Kim J, Jung S, et al.
Br J Cancer
. 2019 Apr;
120(9):941-951.
PMID: 30944457
Background: Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signalling pathway and are attractive targets for cancer therapy. These agents continue to be investigated in KRAS mutant...
8.
Choi E, Kim S, Hong S, Moon J, Shin J, Kim J, et al.
Mol Med Rep
. 2016 Sep;
14(4):3955-60.
PMID: 27599791
Triple-negative breast cancer (TNBC) is a breast cancer subtype that has an aggressive phenotype, is highly metastatic, has limited treatment options and is associated with a poor prognosis. In addition,...
9.
Jung S, Lee D, Moon J, Hong S, Shin J, Hwang I, et al.
Free Radic Biol Med
. 2016 Mar;
95:200-8.
PMID: 27012422
Colon cancer patients with mutant KRAS are resistant to cetuximab, an antibody directed against the epidermal growth factor receptor, which is an effective clinical therapy for patients with wild-type KRAS....
10.
Jo J, Choi E, Shin J, Moon J, Hong S, Lee H, et al.
Mol Cancer Ther
. 2015 Sep;
14(11):2613-22.
PMID: 26351320
The MET receptor tyrosine kinase, the receptor for hepatocyte growth factor (HGF), has been implicated in cancer growth, invasion, migration, angiogenesis, and metastasis in a broad variety of human cancers,...